~~<i id='B40DCFF3C7'><strike id='B40DCFF3C7'><tt id='B40DCFF3C7'><pre id='B40DCFF3C7'></pre></tt></strike></i>~~

Home» leisure time» comprehensive

comprehensive

author：leisure time 2025-09-29 15:18:21 Page View：7

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As billionaires fund anti
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Eli Lilly expects to double planned employment in Boston center

Anartist'srenderingofthebuilding—currentlyunderconstructionalongBoston'sFortPointChannel—whereEliLil

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Studies point to risks of excluding people with obesity from drug trials

AdobePeoplewithobesityoftengounderrepresentedindrugdevelopmenttrials,acriticalgapthatresearcherssayl

WSS

comprehensive

comprehensive

Wikipedia

explore

Studies point to risks of excluding people with obesity from drug trials